Madopar CR, also known as Controlled Release Levodopa/Benserazide, is a medication primarily used in the treatment of Parkinson's disease and parkinsonism. It is a combination drug that contains levodopa, a precursor to dopamine, and benserazide, a decarboxylase inhibitor. The purpose of benserazide is to prevent the premature conversion of levodopa to dopamine outside of the brain, thereby increasing the availability of levodopa for conversion to dopamine within the brain. This is crucial for managing the symptoms of Parkinson's disease, as dopamine is a neurotransmitter that is in short supply in the brains of patients with this condition. The controlled release formulation of Madopar CR is designed to allow for a more steady absorption of the medication, leading to a more consistent therapeutic effect and potentially reducing the occurrence of fluctuations in the patient's condition.